Prediction of treatment outcome and relapse in inflammatory bowel disease

References

• Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477–483.
   PubMed Web of Science ®Google Scholar
• López-Palacios N, Mendoza JL, Taxonera C, et al. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurine in monotherapy. Eur J Intern Med. 2011;22:621–625.
   PubMed Web of Science ®Google Scholar
• Menees S, Higgins P, Korsnes S, et al. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007;13:12–18.
   PubMed Web of Science ®Google Scholar
• Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15:1557–1564.
   PubMed Web of Science ®Google Scholar
• Powell-Tuck J, Dw D, Na B, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci. 1982;27:533–537.
   PubMed Web of Science ®Google Scholar
• Seo M, Okada M, Maeda K, et al. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol. 1998;93:2124–2129.
   PubMed Web of Science ®Google Scholar
• Ricanek P, Brackmann S, Perminow G, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol. 2011;46:1081–1091.
   PubMed Web of Science ®Google Scholar
• Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081–1088.
   PubMed Web of Science ®Google Scholar
• Pagnini C, Menasci F, Festa S, et al. Application of clinical indexes in ulcerative colitis patients in regular follow-up visit: correlation with endoscopic mucosal healing and implication for management. Preliminary results. Eur Rev Med Pharmacol Sci. 2015;19:3674–3681.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the non-invasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.
   PubMed Web of Science ®Google Scholar
• Falvey JD, Hokin T, Meijer B, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21:824–831.
   PubMed Web of Science ®Google Scholar
• Marín-Jiménez I, Nos P, Domènech E, et al. Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study. Am J Gastroenterol. 2016;111:261–268.
   PubMed Web of Science ®Google Scholar
• Tsuda S, Kunisaki R, Kato J, et al. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res. 2018;16:579–587.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Keir ME, Scherl A, et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66:2063–2068.
   PubMed Web of Science ®Google Scholar
• Narula N, Alshahrani AA, Yuan Y, et al. Patient-reported outcomes and endoscopic appearance of ulcerative colitis -a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:411–418.
   Web of Science ®Google Scholar
• Toyonaga T, Kobayashi T, Nakano M, et al. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLos One. 2017;12:e0185131.
   PubMed Web of Science ®Google Scholar
• Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. Gut. 1994;35:231–235.
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV Jr, Wj T, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer S, et al. A review of activity indices and efficacy endopoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–530.
   PubMed Web of Science ®Google Scholar
• Irvine E. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD study group. J Clin Gastroenterol. 1995;20:27–32.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.
   PubMed Web of Science ®Google Scholar
• Chen JM, Liu T, Gao S, et al. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China. World J Gastroenterol. 2017;23:8235–8247.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalization and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88–95.
   PubMed Web of Science ®Google Scholar
• Fukuba N, Ishihara S, Kawashima K, et al. Irritable bowel syndrome-like symptoms associated with endoscopic activity predict ulcerative colitis relapse in patients clinical remission. Intest Res. 2017;15:543–545.
   PubMed Web of Science ®Google Scholar
• Fukuba N, Ishihara S, Tada Y, et al. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol. 2014;49:674–680.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Kip KE, Schraut W, et al. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011;17:118–126.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markeres in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Boone J, Lauche R, et al. Fecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: post hoc analysis of a prospective clinical trial. J Crohn Colitis. 2016;10:786–794.
   PubMed Web of Science ®Google Scholar
• Beigel F, Deml M, Schnitzler F, et al. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF alpha antibodies. PLos One. 2014;9:e99293.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kolho KL, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Staumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.
   PubMed Web of Science ®Google Scholar
• Hosomi S, Yamagami H, Itani S, et al. Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel disease. J Crohn Colitis. 2018;12:87–95.
   PubMed Web of Science ®Google Scholar
• Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin more accurately predicts endoscopic remission of Crohn’s disease than serological biomarker evaluated using balloon-assisted enteroscopy. Inflamm Bowel Dis. 2017;23:2027–2034.
   PubMed Web of Science ®Google Scholar
• Iwamoto F, Matsuoka K, Motobayashi M, et al. Prediction of disease activity of Crohn’s disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol. 2018;33:1984–1989.
   PubMed Web of Science ®Google Scholar
• Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2011;34:911–922.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–576.
   PubMed Web of Science ®Google Scholar
• Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–427.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associated with short- and long-term outcomes of therapy for Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:539–547.
   PubMed Web of Science ®Google Scholar
• Däbritz J, Langhorst J, Lügering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis. 2013;19:1130–1138.
   PubMed Web of Science ®Google Scholar
• Hibi T, Sakuraba A, Watanabe M, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol. 2014;49:254–262.
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastreonterology. 2012;142:63–70.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865–872.
   PubMed Web of Science ®Google Scholar
• Laculli E, Agostini M, Biancone L, et al. C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn’s disease. Cell Death Discov. 2016;2:16032.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol. 2014;20:18367–18374.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. An elevated platelet count increases the risk of relapse in ulcerative colitis patients with mucosal healing. Gut Liver. 2018;12:420–425.
   PubMed Web of Science ®Google Scholar
• Morita Y, Bamba S, Takahashi K, et al. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-ααantibodies in ulcerative colitis. Scand J Gastroenterol. 2016;51:934–941.
   PubMed Web of Science ®Google Scholar
• Dontan I, Ron Y, Yanai H, et al. Patient Factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247–2259.
   PubMed Web of Science ®Google Scholar
• Arias MT, Casteele NV, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531–538.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Hosomi S, Yamagami H, et al. Neutrophil-to-lymphocyte ratio for predicting loss of response to infliximab in ulcerative colitis. PLos One. 2017;12:e0169845.
   PubMed Web of Science ®Google Scholar
• Kalla R, Kennedy NA, Ventham NT, et al. Serum calprotectin: A novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol. 2016;111:1796–1805.
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Ono N, Imaizumi A, et al. Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission. PLoS One. 2015;10:e0140716.
   PubMed Web of Science ®Google Scholar
• Shinzaki S, Matsuoka K, Iijima H, et al. Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohn Colitis. 2017;11:84–91.
   PubMed Web of Science ®Google Scholar
• de Bruyn M, Arijs I, De Hertogh G, et al. Serum neutrophil gelantinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate marker for mucosal healing in patients with Crohn’s disease. J Crohn Colitis. 2015;9:1079–1087.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851–1858.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
   PubMed Web of Science ®Google Scholar
• Theede K, Holck S, Ibsen P, et al. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patinets with mucosal healing of ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:1929–1936.
   PubMed Web of Science ®Google Scholar
• Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873–880.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kim MJ, Song EM, et al. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol. 2017;17:110.
   PubMed Web of Science ®Google Scholar
• Mak YW, Buisson A, Andersen MJ Jr., et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci. 2018;63:1201–1294.
   Web of Science ®Google Scholar
• Yamaguchi S, Takeuchi Y, Arai K, et al. Fecal calprotectin is a clinically relevant biomarker of mucoal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol. 2016;31:93–98.
   PubMed Web of Science ®Google Scholar
• Carlsen K, Fiis LB, Elsberg H, et al. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol. 2018;53:825–830.
   PubMed Web of Science ®Google Scholar
• Shi HY, Chan FKL, Chan AWH, et al. Accuracy of faecal immunochemical test to predict endoscopic and histological healing in ulcerative colitis: a prospective study based on validated histological scores. J Crohn Colitis. 2017;11:1071–1077.
   PubMed Web of Science ®Google Scholar
• Patel A, Panchal H, Dubinsky MC. Fecal calprotectin levels predict histological healing in ulcerative colitis. Inflamm Bowel Dis. 2017;23:1600–1604.
   PubMed Web of Science ®Google Scholar
• Ma C, Lumb R, Walker EV, et al. Noninvasive fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: a prospective cohort study. Inflamm Bowel Dis. 2017;23:1643–1649.
   PubMed Web of Science ®Google Scholar
• Urushikubo J, Yanai S, Nakamura S, et al. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol. 2018;24:4384–4392.
   PubMed Web of Science ®Google Scholar
• Lin WC, Wong JM, Tung CC, et al. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastorenterol. 2015;21:13566–13573.
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Yamamoto T, Umegae S, et al. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol. 2018;18:120.
   PubMed Web of Science ®Google Scholar
• Kristensen V, Røseth A, Ahmad T, et al. Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol Res Pract. 2017;2017:2098293.
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Faggiani R, et al. Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: a real-life multicenter, observational study in primary inflammatory bowel disease centers. Medicine (Baltimore). 2018;97:e11897.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Bressler B, Curtis R, et al. Fecal calprotectin responses following induction therapy with vedolizumab in moderate to severe ulcerative colitis. A post hoc analysis of GEMINI 1. Inflamm Bowel Dis.  2019;25:803–810.
   Google Scholar
• Sandborn WJ, Panés J, Zhang H, et al. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology. 2016;150:96–102.
   PubMed Web of Science ®Google Scholar
• Gaudi L, Marzo M, Andrisani G, et al. Faecal calprotectin assay after induction with anti-tumour necrosis factor α agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year. Dig Liver Dis. 2014;46:974–979.
   PubMedGoogle Scholar
• Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohn Colitis. 2013;7:641–651.
   PubMedGoogle Scholar
• Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14:1392–1398.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Garnero P, Moussata D, et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonisits in patients with Crohn’s disease. Inflamm Bowel Dis. 2015;21:331–336.
   PubMed Web of Science ®Google Scholar
• D’incà R, Ed P, Vd L, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007–2014.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190–1198.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shimoyama T, Umegae S, et al. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol. 2018;9:136.
   PubMed Web of Science ®Google Scholar
• García-Sánchez V, Igresias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohn Colitis. 2010;4:144–152.
   PubMed Web of Science ®Google Scholar
• De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111–2117.
   PubMed Web of Science ®Google Scholar
• Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohn Colitis. 2015;9:33–40.
   PubMed Web of Science ®Google Scholar
• Lasson A, Simrén M, Stotzer PO, et al. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis. 2013;19:576–581.
   PubMed Web of Science ®Google Scholar
• Brooks AJ, Sebastian S, Cross SS, et al. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn’s disease in established remission. J Crohn Colitis. 2017;11:1456–1462.
   PubMed Web of Science ®Google Scholar
• Naismith GD, Smith LA, Barry SJE, et al. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohn Colitis. 2014;8:1022–1029.
   PubMed Web of Science ®Google Scholar
• Ferreiro-Igresias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, et al. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn’s disease patients on maintenance treatment with adalimumab. Scand J Gastroenterol. 2016;51:442–447.
   PubMed Web of Science ®Google Scholar
• Kostas A, Siakavellas SI, Kosmidis C, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol. 2017;23:7387–7396.
   PubMed Web of Science ®Google Scholar
• Bachiller MTH, Andres JB, Salazar LF, et al. The utility of faecal calprotectin to predict post-operative recurrence in Crohn’s disease. Scand J Gastroenterol. 2016;6:720–726.
   Google Scholar
• Lopes S, Andrade P, Rodrigues-Pinto E, et al. Fecal marker levels as predictors of need for endoscopic balloon dilatation in Crohn’s disease patients with anastomotic strictures. World J Gastroenterol. 2017;23:6482–6490.
   PubMed Web of Science ®Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148:938–947.
   PubMed Web of Science ®Google Scholar
• Liu R, Guo Z, Cao L, et al. Profile of consecutive fecal calprotectin levels in the perioperative period and its predictive capacity for early endoscopic recurrence in Crohn’s disease. Dis Colon Rectum. 2019;62:318–326.
   Web of Science ®Google Scholar
• Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669–673.
   PubMed Web of Science ®Google Scholar
• van Rheenen PF Role of fecal calprotectin testing to redict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012;18:2018–2025
   Google Scholar
• Zubin G, Peter L. Predicting endoscopic Crohn’s disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis. 2015;21:1386–1391.
   PubMed Web of Science ®Google Scholar
• Diederen K, Hoekman DR, Leek A, et al. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther. 2017;45:951–960.
   PubMed Web of Science ®Google Scholar
• Ziv-Baran T, Hussey S, Sladek M, et al. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease. Aliment Pharmacol Ther. 2018;48:1242–1250.
   PubMed Web of Science ®Google Scholar
• Weinstein-Nakar I, Focht G, Church P, et al. Associations among mucosal and transmural healing and fecal level of calprotectin in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16:1089–1097.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108:83–89.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Hiraoka S, Takahashi S, et al. Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse. J Crohn Colitis. 2018;12:71–76.
   PubMed Web of Science ®Google Scholar
• Inokuchi T, Kato J, Hiraoka S, et al. Fecal immunochemical test versus fecal calprotecctin for prediction of mucosal healing in Crohn’s disease. Inflamm Bowel Dis. 2016;22:1078–1085.
   PubMed Web of Science ®Google Scholar
• Kuriyama M, Kato J, Takemoto K, et al. Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test. World J Gastroenterol. 2010;16:1110–1114.
   PubMed Web of Science ®Google Scholar
• Hiraoka S, Kato J, Nakarai A, et al. Consecutive measurements by faecal immunochemical test in quiescent ulcerative colitis patients can detect clinical relapse. J Crohn Colitis. 2016;10:687–694.
   PubMed Web of Science ®Google Scholar
• Hiraoka S, Inokuchi T, Nakarai A, et al. Fecal immunochemical test and fecal calprotectin results show different profiles in disease monitoring for ulcerative colitis. Gut Liver. 2018;12:142–148.
   PubMed Web of Science ®Google Scholar
• Rispo A, Imperatore N, Testa A, et al. Diagnostic accuracy of ultrasonography in the detection of postsurgical recurrence in Crohn’s disease: a systematic review with meta-analysis. Inflamm Bowel Dis. 2018;24:977–988.
   PubMed Web of Science ®Google Scholar
• Narang V, Kaur R, Garg B, et al. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intest Res. 2018;16:55–61.
   PubMed Web of Science ®Google Scholar
• Jauregui-Amezaga A, Lópes-Cerón M, Aceituno M, et al. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study. Inflamm Bowel Dis. 2014;20:1187–1193.
   PubMed Web of Science ®Google Scholar
• Ozaki R, Kobayashi T, Okabayashi S, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohn Colitis. 2018;12:1–7.
   PubMedGoogle Scholar
• Karstensen JG, Săftoiu A, Brynskov J, et al. Confocal laser endomicroscopy: a novel method for prediction of relapse in Crohn’s disease. Endoscopy. 2016;48:364–372.
   PubMed Web of Science ®Google Scholar
• Li CQ, Liu J, Ji R, et al. Use of confocal laser endomicroscopy to predict relapse of ulcerative colitis. BMC Gastroenterol. 2014;14:45.
   PubMed Web of Science ®Google Scholar
• Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel disease. Clin Gastroenterol Heptaol. 2014;12:80–84.
   PubMed Web of Science ®Google Scholar
• Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-ααtherapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550–557.
   PubMed Web of Science ®Google Scholar
• Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn’s disease. J Crohn Colitis. 2016;10:510–515.
   PubMedGoogle Scholar
• Juncadella A, Papamichael K, Vaughn B, et al. Maintenance adalimumab concentrations are associated with biochemical, endoscopic, and histologic remission in inflammatory bowel disease. Dig Dis Sci. 2018;63:3067–3073.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rakowsky S, Rivera C, et al. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn’s disease. Inflamm Bowel Dis. 2018;24:2266–2271.
   PubMed Web of Science ®Google Scholar
• Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19:2568–2576.
   PubMed Web of Science ®Google Scholar
• Roblin X, Duru G, Williet N, et al. Development and internal validation of a model using fecal calprotectin in combination with infliximab trough levels to predict clinical relapse in Crohn’s disease. Inflamm Bowel Dis. 2017;23:126–132.
   PubMed Web of Science ®Google Scholar
• Bodini G, Savarino V, Peyrin-Biroulet L, et al. Low serum trough levels are associated with post-surgical recurrence in Crohn’s disease patients undergoing prophylaxis with adalimumab. Dig Liver Dis. 2014;46:1043–1046.
   PubMedGoogle Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Anti-TNF therapeutic drug monitoring in postoperative Crohn’s disease. J Crohn Colitis. 2018;12:653–661.
   PubMed Web of Science ®Google Scholar
• Fay S, Ungar B, Paul S, et al. The association between drug levels and endoscopic recurrence in postoperative patients with Crohn’s disease treated with tumor necrosis factor inhibitors. Inflamm Bowel Dis. 2017;23:1924–1929.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Casteele NV, Gils A, et al. Long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015;13:1103–1110.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y, Ungar B, et al. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015;42:356–364.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16:1937–1946.
   PubMed Web of Science ®Google Scholar
• Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19:1034–1042.
   PubMed Web of Science ®Google Scholar
• Inoue K, Aotmatsu T, Yoden A, et al. Usefulness of a novel rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases. J Gastroenterol Hepatol. 2014;29:1406–1412.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar
• Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415–1422.
   PubMed Web of Science ®Google Scholar
• Cushing KC, Mclean R, McDonald KG, et al. Predicting risk of postoperative disease recurrence in Crohn’s disease: patients with indolent Crohn’s disease have distinct whole transcriptome profiles at the time of first surgery. Inflamm Bowel Dis. 2019;25:180–193.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2279–2289.
   Google Scholar
• Hiraoka S, Takashima S, Inokuchi T, et al. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces. Intest Res. 2018. epub
   Web of Science ®Google Scholar